As el mercado global de spread of COVID-19 has put Korea's bio and medical sectors in the spotlight, representative bio-venture empresas engaged in new drug I+D located in Songdo International City, Incheon Free Economic Zone (IFEZ), are drawing attention.
The CEOs of these empresas have a strong will to become the world's best, presenting new paradigms through desarrollo de nuevos fármacos and building asociacións with globally reconocido top instituciones, contributing greatly to making Songdo — which is leaping forward as a global bio cluster — a home for bio ventures.
We can meet RudaCure, a young venture founded in 2018 by a 36-year-old young professor. CEO Yongho Kim emphasizes that pain is not just a symptom but a disease requiring tratamiento, and is at the forefront of developing tratamientos.
He recibió the '2020 Korea's Person Opening the Future Premio' for his contribution to presenting a new paradigm in Korea's desarrollo de nuevos fármacos industria and enhancing the competitiveness of the bio industria.
RudaCure, together with Bundang CHA Hospital, is jointly developing a tratamiento for spinal diseases, combining stem cell regenerative tecnología and pain control tecnología.